The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | The aberrant expression of WNK2 in WM and WNK2 as a potential therapeutic target
Maria Luisa Guerrera, MD, Dana-Farber Cancer Institute, Boston, MA, discusses research on the expression of WNK2, a tumor suppressor gene with unique behavior in Waldenström’s macroglobulinemia (WM). Her team identified new isoforms of WNK2, which may offer novel therapeutic targets, particularly in cases of treatment resistance. However, further studies are needed to confirm these preliminary findings. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
